What happened
The American Medical Association (AMA) and the Federation of State Medical Boards (FSMB) published a proceedings report titled *AI and the Practice of Medicine: Examining Accountability and Responsibility in the AI Era*. The report stems from a one‑day stakeholder forum held on Sept. 14, 2026 in Washington, D.C., which brought together state medical board officials, physicians, specialty societies, patient advocates, health‑system leaders, technology developers, regulators, policymakers, legal experts and academics. Participants debated how the growing use of autonomous and semi‑autonomous AI tools—systems that can perform functions traditionally reserved for licensed physicians—should reshape physician liability, state‑board oversight, and the physician‑patient relationship. The document synthesizes the discussion, highlights key learnings, and sets out a roadmap for future work, including a draft guidance package the FSMB plans to release for public comment in December 2026 and a formal vote by its House of Delegates in April 2027.
On Sept. 14, 2026, the AMA and FSMB co‑hosted a one‑day forum in Washington, D.C., gathering a diverse set of participants—including state medical board representatives, physicians, specialty societies, patient advocates, health‑system leaders, AI developers, regulators, policymakers, legal scholars and academics—to discuss the implications of AI tools that can perform clinical functions traditionally performed by licensed physicians.
The forum focused on three core questions: (1) How should physician responsibility evolve when AI performs autonomous or semi‑autonomous tasks? (2) What role should state medical boards play in overseeing AI‑driven care? and (3) How can regulatory and liability frameworks be modernized to protect patients while fostering innovation?
The resulting proceedings report, titled *AI and the Practice of Medicine: Examining Accountability and Responsibility in the AI Era*, synthesizes the viewpoints expressed, noting that AI is already reshaping care teams and the physician’s role, though participants differed on the speed of change. The report emphasizes that existing regulatory, licensure and liability structures were not designed for AI and need updating because clinicians and patients are adopting AI faster than the health system can adapt.
Quotes from FSMB President and CEO Humayun J. Chaudhry, DO, MACP, and AMA CEO John Whyte, MD, MPH, underscore the urgency: both stress that patient protection remains paramount and that clear accountability mechanisms must keep pace with AI adoption.
The AMA’s Center for Digital Health and AI and the FSMB’s Workgroup on the Regulation of Artificial Intelligence in the Practice of Medicine will continue to develop the identified priorities. The FSMB plans to release draft guidance for public comment in December 2026, with a formal vote by its House of Delegates scheduled for April 2027.
Source details: southfloridahospitalnews.com
Why it matters
The report marks a coordinated, high‑level effort by two of the most influential bodies governing U.S. medical practice to confront the regulatory and liability gaps created by AI‑driven clinical tools. Existing licensure, liability and oversight frameworks were designed for human clinicians, not for software that can diagnose, recommend treatment or even execute certain procedures. By convening a broad cross‑section of stakeholders, the AMA and FSMB are establishing a shared foundation for policy development, which could shape how state medical boards draft rules, how physicians document AI‑assisted care, and how liability is allocated when AI errors occur. The forthcoming draft guidance and public‑comment process will give clinicians, developers, and patient groups a chance to influence standards before they become binding, potentially affecting the rollout of AI tools across hospitals, clinics and telehealth platforms nationwide. Clear accountability pathways are also essential for maintaining patient trust and ensuring that AI adoption does not outpace patient‑protection mechanisms.
Regulatory Gap: Current medical licensure and liability rules assume a human clinician makes all diagnostic and treatment decisions. AI tools that can autonomously generate diagnoses or treatment recommendations fall outside these assumptions, creating uncertainty about who is legally responsible when errors occur.
Patient Trust: Clear accountability frameworks are essential to maintain patient confidence in AI‑augmented care. Without transparent responsibility lines, patients may be reluctant to accept AI‑driven recommendations, slowing adoption of potentially beneficial technologies.
Industry Impact: Guidance from the AMA and FSMB will influence how AI vendors design products to meet regulatory expectations, potentially shaping features such as , audit trails, and clinician oversight requirements.
State Board Consistency: By coordinating a unified approach, the FSMB can help state medical boards avoid a patchwork of divergent rules, reducing compliance complexity for multi‑state health systems and AI developers.
Future Policy Development: The report’s recommendations will likely inform federal discussions on AI in healthcare, including possible updates to the FDA’s software as a medical device (SaMD) framework and congressional hearings on AI liability.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
crm_get_transaction(id='4092').Why can ethical evaluation not be reduced to one model score?
What to watch next
Key upcoming milestones include the FSMB’s draft AI oversight guidance slated for public comment in December 2026, the AMA Center for Digital Health and AI’s policy proposals, and the FSMB House of Delegates vote in April 2027. Watch for state medical board adoption of consistent AI‑specific regulations, any legislative proposals at the federal level that reference the report’s recommendations, and how major AI vendors respond with compliance roadmaps. Additionally, monitor how health systems incorporate the guidance into clinical workflows and whether liability insurers adjust coverage terms for AI‑enabled care.
December 2026: Release of FSMB draft guidance on AI oversight for public comment. Stakeholder feedback will reveal areas of consensus and contention.
April 2027: Formal vote by the FSMB House of Delegates on adopting the AI oversight guidance. Adoption could trigger state‑level rulemaking.
AMA policy proposals: The AMA Center for Digital Health and AI will publish its own set of recommendations, which may include best‑practice standards for AI integration, physician training, and economic sustainability models.
Legislative activity: Monitor any federal or state bills that cite the AMA/FSMB report, especially those addressing AI liability, telemedicine, or digital health reimbursement.
Vendor response: AI developers may issue compliance roadmaps or adjust product features (e.g., adding clinician‑in‑the‑loop controls) to align with emerging guidance.